TOXICOLOGICAL PROFILE FOR
3,3’-DICHLOROBENZIDINE

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

December 1998
DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.
A Toxicological Profile for 3,3’-Dichlorobenzidine was released in September 1997. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Jeffrey P. Koplan, M.D., M.P.H.
Administrator
Agency for Toxic Substances and Disease Registry
The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see Federal Register notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.
QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement:
The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Health Effects:
Specific health effects of a given hazardous compound are reported by route of exposure, by type of health effect (death, systemic, immunologic, reproductive), and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 2.6 Children’s Susceptibility
Section 5.6 Exposures of Children

Other Sections of Interest:
Section 2.7 Biomarkers of Exposure and Effect
Section 2.10 Methods for Reducing Toxic Effects

ATSDR Information Center
Phone: 1-800-447-1544 (to be replaced by 1-888-42-ATSDR in 1999)
or 404-639-6357
Fax: 404-639-6359
E-mail: atsdric@,cdc.nov
Internet: http://atsdrl.atsdr.cdc.nov:8080

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History-The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity; and numerous chemical-specific case studies.
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III-Medical Management Guidelines for Acute Chemical Exposures-is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (‘ToxFaqs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH)
focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH)
conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS)
is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC)
has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 10 10 Vermont Avenue, NW, #5 13, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: aoec@dgs.dnsys.com • AOEC Clinic Director: http://occ-envmed.mc.duke.edu/oem/aoec.htm.

The American College of Occupational and Environmental Medicine (ACOEM)
is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Lori L. Miller, M.P.H.
ATSDR Division of Toxicology, Atlanta, GA

Cassandra Smith-Simon, M.S.
ATSDR, Division of Toxicology, Atlanta, GA

Fernando Llados, Ph.D.
Research Triangle Institute, Research Triangle Park, NC

Steve Kueberuwa, M.S.
Research Triangle Institute, Research Triangle Park, NC

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.

2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile; and makes recommendations for derivation of MRLs.

3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
A peer review panel was assembled for 3,3'-dichlorobenzidine. The panel consisted of the following members:

1. Dr. Herbert Cornish, Private Consultant, 830 W. Clark Rd., Ypsilanti, MI 48 198;
2. Dr. Arthur Gregory, Private Consultant, 1 Gregory Lane, Luray, VA 22835;
3. Dr. Philip Leber, Private Consultant, 1344 Jefferson Ave., Akron, OH 443 13; and
4. Dr. Robert Rubin, Johns Hopkins School of Public Health, Environmental Health Sciences, Baltimore, MD 21205.

These experts collectively have knowledge of 3,3’-dichlorobenzidine’s physical and chemical properties, toxicokinetics, key health endpoints, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(1)( 13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers’ comments and determined which comments will be included in the profile. A listing of the peer reviewers’ comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile’s final content. The responsibility for the content of this profile lies with the ATSDR.
# CONTENTS

FOREWORD ................................................................. v

QUICK REFERENCE FOR HEALTH CARE PROVIDERS .................... vii

CONTRIBUTORS .............................................................. ix

PEER REVIEW .............................................................. xi

LIST OF FIGURES .......................................................... xvii

LIST OF TABLES ............................................................ xix

1. PUBLIC HEALTH STATEMENT .............................................. 1
   1.1 WHAT IS 3,3'-DICHLOROBENZIDINE? ............................... 1
   1.2 WHAT HAPPENS TO 3,3'-DICHLOROBENZIDINE WHEN IT ENTERS THE ENVIRONMENT? ........................................... 2
   1.3 HOW MIGHT I BE EXPOSED TO 3,3'-DICHLOROBENZIDINE? ........... 2
   1.4 HOW CAN 3,3'-DICHLOROBENZIDINE ENTER AND LEAVE MY BODY? ........... 3
   1.5 HOW CAN 3,3'-DICHLOROBENZIDINE AFFECT MY HEALTH? ............... 3
   1.6 HOW CAN 3,3'-DICHLOROBENZIDINE AFFECT CHILDREN? .......... 5
   1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO 3,3'-DICHLOROBENZIDINE? .................................... 6
   1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 3,3'-DICHLOROBENZIDINE? ......................... 7
   1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .......................... 7
   1.10 WHERE CAN I GET MORE INFORMATION? ......................... 9

2. HEALTH EFFECTS .......................................................... 11
   2.1 INTRODUCTION ......................................................... 11
   2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .............. 11
      2.2.1 Inhalation Exposure ........................................... 12
         2.2.1.1 Death ...................................................... 13
         2.2.1.2 Systemic Effects ......................................... 13
         2.2.1.3 Immunological and Lymphoreticular Effects .......... 14
         2.2.1.4 Neurological Effects .................................... 14
         2.2.1.5 Reproductive Effects ................................... 14
         2.2.1.6 Developmental Effects .................................. 14
         2.2.1.7 Genotoxic Effects ....................................... 14
         2.2.1.8 Cancer .................................................... 15
      2.2.2 Oral Exposure .................................................... 17
         2.2.2.1 Death ...................................................... 17
         2.2.2.2 Systemic Effects ......................................... 24
         2.2.2.3 Immunological and Lymphoreticular Effects .......... 25
         2.2.2.4 Neurological Effects .................................... 25
         2.2.2.5 Reproductive Effects ................................... 26
2.2.2.6 Developmental Effects ........................................... 26
2.2.2.7 Genotoxic Effects .............................................. 26
2.2.2.8 Cancer ............................................................ 27
2.2.3 Dermal Exposure ...................................................... 29
2.2.3.1 Death ............................................................. 29
2.2.3.2 Systemic Effects ................................................. 30
2.2.3.3 Immunological and Lymphoreticular Effects ................. 32
2.2.3.4 Neurological Effects ............................................ 32
2.2.3.5 Reproductive Effects ........................................... 32
2.2.3.6 Developmental Effects ......................................... 32
2.2.3.7 Genotoxic Effects .............................................. 32
2.2.3.8 Cancer ............................................................ 32

2.3 TOXICOKINETICS ....................................................... 34
2.3.1 Absorption .......................................................... 34
2.3.1.1 Inhalation Exposure .......................................... 34
2.3.1.2 Oral Exposure .................................................. 35
2.3.1.3 Dermal Exposure .............................................. 35
2.3.2 Distribution .......................................................... 35
2.3.2.1 Inhalation Exposure .......................................... 36
2.3.2.2 Oral Exposure .................................................. 36
2.3.2.3 Dermal Exposure .............................................. 37
2.3.3 Metabolism .......................................................... 37
2.3.4 Elimination and Excretion ......................................... 39
2.3.4.1 Inhalation Exposure .......................................... 39
2.3.4.2 Oral Exposure .................................................. 39
2.3.4.3 Dermal Exposure .............................................. 40
2.3.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models ....................................................... 40

2.4 MECHANISMS OF ACTION ............................................. 43
2.4.1 Pharmacokinetic Mechanisms .................................... 43
2.4.2 Mechanisms of Toxicity .......................................... 44
2.4.3 Animal-to-Human Extrapolations ................................ 45

2.5 RELEVANCE TO PUBLIC HEALTH ..................................... 46

2.6 CHILDREN'S SUSCEPTIBILITY ........................................ 59

2.7 BIOMARKERS OF EXPOSURE AND EFFECT .......................... 62
2.7.1 Biomarkers Used to Identify or Quantify Exposure to 3,3'-Dichlorobenzidine .................................................. 63
2.7.2 Biomarkers Used to Characterize Effects Caused by 3,3'-Dichlorobenzidine .................................................. 64

2.8 INTERACTIONS WITH OTHER CHEMICALS .......................... 64

2.9 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ..................... 65

2.10 METHODS FOR REDUCING TOXIC EFFECTS .......................... 65
2.10.1 Reducing Peak Absorption Following Exposure ................. 65
2.10.2 Reducing Body Burden ........................................... 66
2.10.3 Interfering with the Mechanism of Action for Toxic Effects .................................................. 66

2.11 ADEQUACY OF THE DATABASE ....................................... 66
2.11.1 Existing Information on Health Effects of 3,3'-Dichlorobenzidine .................................................. 67
2.11.2 Identification of Data Needs ..................................... 69
2.11.3 Ongoing Studies ................................................... 75
APPENDICES

A. ATSDR MINIMAL RISK LEVEL AND WORKSHEETS ........................................... A-1
B. USER'S GUIDE .................................................................................................. B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS .............................................. C-1
# LIST OF FIGURES

2-1  Levels of Significant Exposure to 3,3'-Dichlorobenzidine—Oral ........................................ 22

2-2  Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance ........................................... 42

2-3  Existing Information on Health Effects of 3,3'-Dichlorobenzidine ........................................ 68

5-1  Frequency of NPL Sites with 3,3'-Dichlorobenzidine Contamination ................................. 90
LIST OF TABLES

2-1 Levels of Significant Exposure to 3,3'-Dichlorobenzidine—Oral ........................................ 18
2-2 Levels of Significant Exposure to 3,3'-Dichlorobenzidine—Dermal ........................................ 31
2-3 Genotoxicity of 3,3'-Dichlorobenzidine In Vivo ................................................................. 53
2-4 Genotoxicity of 3,3'-Dichlorobenzidine In Vitro ................................................................. 54
3-1 Chemical Identity of 3,3'-Dichlorobenzidine ................................................................. 78
3-2 Physical and Chemical Properties of 3,3'-Dichlorobenzidine ........................................ 79
4-1 Facilities That Manufacture or Process 3,3'-Dichlorobenzidine ........................................ 82
5-1 Releases to the Environment from Facilities That Manufacture or Process
3,3'-Dichlorobenzidine ................................................................. 88
6-1 Analytical Methods for Determining 3,3'-Dichlorobenzidine and Metabolites in
Biological Samples ................................................................. 108
6-2 Analytical Methods for Determining 3,3'-Dichlorobenzidine in Environmental Samples .... 111
7-1 Regulations and Guidelines Applicable to 3,3'-Dichlorobenzidine .................................... 118